

# China Feihe (6186 HK)

## Completion of channel restructuring continues to drive a steady 2H recovery

We moderately trim our 2022/23E earnings by 6-7% p.a as we now attempt to factor-in 1) a lower GPM (by average 0.8pp) due to higher non-infant milk formula contribution and 2) a 1.5pp higher selling expense. Our forecast in general is at the low end/ slightly below management guidance, as we believe a low birth rate could compound with an intensifying competition to weigh on margins and drive up promotion expenses. Despite this, Feihe's sequential sales recovery sustains our BUY rating.

- Guidance maintained.** Management targets DD HoH revenue growth in 2H and LSD revenue decline for 2022E (1H22: -16.2% YoY). Margin-wise, Feihe indicated that 2H GPM and NPM will improve HoH, with full year GPM and NPM standing at 66-68% (1H22: 68%, 2021: 70.3%) and c.26% (1H22: 23.3%, 2021: 30.2%), respectively. With that, this implies selling expense ratio to stabilise at c.30% in longer term (1H22: 32.5%).
- Sales mix upgrade has been an important topline support.** While China's IMF market has been under pressure in recent three years, super premium and super premium+ (teens of growth YoY in 1H22) segments maintained a steadily upward momentum, according to management. Feihe would be a major beneficiary from this trend, given a heavy weight (c.59% in 1H) of these segments in its revenue structure.
- New health and nutrition related product categories could become important topline drivers in longer term.** New product categories, including children milk powder (stage 4 products accounted for c.12% of infant milk powder revenue in 1H) and adult milk powder (still small revenue contribution), are making increasing revenue contribution (in % terms). The company is also looking at opportunities for expanding into other categories, such as cheese and infant complementary food. Margins could still trend down in longer term with increasing contribution from children (GPM c.60%) and adult milk powder (GPM of premium SKUs c.50%).
- Valuation.** Our new TP is based on an unchanged 11.5x end-22E P/E which still represents -1sd below its long term average. In our view, the low earnings visibility of the IMF industry has not convinced us of a valuation roll-over at the moment.

### Earnings Summary

(YE 31 Dec)	FY20A	FY21A	FY22E	FY23E	FY24E
Revenue (RMB mn)	18,592	22,776	21,177	23,536	25,851
YoY growth (%)	35.5	22.5	(7.0)	11.1	9.8
Net profit (RMB mn)	7,436.9	6,871.0	5,228.9	6,112.1	6,672.2
EPS (Basic) (RMB)	0.83	0.77	0.59	0.68	0.75
YoY growth (%)	72.6	(7.5)	(23.9)	16.9	9.2
Consensus EPS (RMB)	na	na	0.68	0.77	0.86
P/E (x)	15.9	18.6	9.3	8.0	7.3
P/B (x)	6.6	6.1	2.1	1.8	1.6
Yield (%)	1.9	2.7	4.3	5.0	5.5
ROE (%)	48.3	35.5	24.0	24.7	23.1
Net gearing (%)	Net cash	Net cash	Net cash	Net cash	Net cash

Source: Company data, Bloomberg, CMBIGM estimates

**BUY (Maintain)**

**Target Price** **HK\$7.60**

(Previous TP) HK\$8.40

**Up/Downside** **28.3%**

**Current Price** **HK\$5.92**

**China Consumer Staples-  
Food and beverages**

**Joseph WONG**

(852) 3900 0838

josephwong@cmbi.com.hk

**Xiaohui ZHENG**

(852) 3900 0838

zhengxiaohui@cmbi.com.hk

#### Stock Data

Mkt Cap (HK\$ mn)	54,248.6
Avg 3 mths t/o (HK\$ mn)	7.2
52w High/Low (HK\$)	13.96/5.80
Total Issued Shares (mn)	8,893.2

Source: FactSet

#### Shareholding Structure

Garland Glory Holdings Limited	43.6%
North Haven Private Equity	7.8%
Asia IMF Hold	


Source: HKEx

#### Share Performance

	Absolute	Relative
1-mth	-8.3%	-3.4%
3-mth	-28.8%	-19.8%
6-mth	-27.8%	-22.8%

Source: FactSet

#### 12-mth Price Performance



Source: FactSet

#### Related Reports

- [China Feihe \(6186 HK\) – 1H softer than expected: a lower 2022E despite a sequentially better 2H – 25 Jul 2022](#)
- [China Feihe - 2H sets to recover when channel restructuring completes as planned – 30 Jun 2022](#)

**Figure 1: Earnings revision**


RMB mn	New			Old			Diff (%)		
	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E
Revenue	21,177	23,536	25,851	21,156	23,593	26,009	0.1%	-0.2%	-0.6%
Gross Profit	14,116	15,821	17,484	14,400	15,931	17,400	-2.0%	-0.7%	0.5%
EBIT	7,389	8,621	9,405	7,763	9,169	9,911	-4.8%	-6.0%	-5.1%
Net profit	5,229	6,112	6,672	5,564	6,572	7,103	-6.0%	-7.0%	-6.1%
EPS (RMB)	0.57	0.67	0.73	0.61	0.72	0.78	-6.0%	-7.0%	-6.1%
Gross Margin	66.7%	67.2%	67.6%	68.1%	67.5%	66.9%	-1.4ppt	-0.3ppt	0.7ppt
EBIT Margin	34.9%	36.6%	36.4%	36.7%	38.9%	38.1%	-1.8ppt	-2.2ppt	-1.7ppt
Net Margin	24.7%	26.0%	25.8%	26.3%	27.9%	27.3%	-1.6ppt	-1.9ppt	-1.5ppt

Source: Company data, CMBIGM estimates


**Figure 2: CMBIGM estimates vs consensus**

RMB mn	CMBIGM			Consensus			Diff (%)		
	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E
Revenue	21,177	23,536	25,851	22,631	25,313	28,120	-6.4%	-7.0%	-8.1%
Gross Profit	14,116	15,821	17,484	15,239	17,075	18,894	-7.4%	-7.3%	-7.5%
Operating Profit	7,389	8,621	9,405	7,608	9,661	10,661	-2.9%	-10.8%	-11.8%
Net profit	5,229	6,112	6,672	6,200	7,011	7,761	-15.7%	-12.8%	-14.0%
EPS (RMB)	0.57	0.67	0.73	0.68	0.77	0.86	-15.3%	-12.4%	-14.3%
Gross Margin	66.7%	67.2%	67.6%	67.3%	67.5%	67.2%	-0.7ppt	-0.2ppt	0.4ppt
EBIT Margin	34.9%	36.6%	36.4%	33.6%	38.2%	37.9%	1.3ppt	-1.5ppt	-1.5ppt
Net Margin	24.7%	26.0%	25.8%	27.4%	27.7%	27.6%	-2.7ppt	-1.7ppt	-1.8ppt

Source: Company data, CMBIGM estimate

**Figure 3: 1-year forward P/E chart**

Source: Bloomberg, CMBIGM estimates

**Figure 4: Trailing P/B chart**

Source: Bloomberg, CMBIGM estimates

## Financial Summary

INCOME STATEMENT	2019A	2020A	2021A	2022E	2023E	2024E
<b>YE 31 Dec (RMB mn)</b>						
<b>Revenue</b>	<b>13,722</b>	<b>18,592</b>	<b>22,776</b>	<b>21,177</b>	<b>23,536</b>	<b>25,851</b>
Cost of goods sold	(4,112)	(5,112)	(6,769)	(7,061)	(7,715)	(8,367)
<b>Gross profit</b>	<b>9,610</b>	<b>13,480</b>	<b>16,008</b>	<b>14,116</b>	<b>15,821</b>	<b>17,484</b>
Selling expense	(3,848)	(5,263)	(6,729)	(7,200)	(7,532)	(8,272)
Admin expense	(913)	(1,161)	(1,208)	(1,271)	(1,412)	(1,551)
Others	819	2,788	1,774	1,744	1,744	1,744
<b>Operating profit</b>	<b>5,668</b>	<b>9,844</b>	<b>9,844</b>	<b>7,389</b>	<b>8,621</b>	<b>9,405</b>
<b>EBITDA</b>	<b>5,849</b>	<b>10,110</b>	<b>10,288</b>	<b>7,899</b>	<b>9,222</b>	<b>10,089</b>
Depreciation	(181)	(266)	(442)	(510)	(601)	(684)
Other amortisation	(0)	(0)	(1)	0	0	0
<b>Net interest income/(expense)</b>	<b>15</b>	<b>74</b>	<b>81</b>	<b>87</b>	<b>91</b>	<b>91</b>
Other income/expense	0	(18)	(253)	(116)	(116)	(116)
<b>Pre-tax profit</b>	<b>5,683</b>	<b>9,900</b>	<b>9,672</b>	<b>7,361</b>	<b>8,596</b>	<b>9,380</b>
Income tax	(1,748)	(2,464)	(2,757)	(2,098)	(2,451)	(2,674)
<b>After tax profit</b>	<b>3,935</b>	<b>7,437</b>	<b>6,915</b>	<b>5,262</b>	<b>6,145</b>	<b>6,706</b>
Minority interest	0	0	(44)	(33)	(33)	(33)
<b>Net profit</b>	<b>3,935</b>	<b>7,437</b>	<b>6,871</b>	<b>5,229</b>	<b>6,112</b>	<b>6,672</b>
<b>Core net profit</b>	<b>4,072</b>	<b>6,046</b>	<b>6,871</b>	<b>5,229</b>	<b>6,112</b>	<b>6,672</b>
Net dividends	1,574	2,287	3,462	2,092	2,445	2,669
<b>BALANCE SHEET</b>						
<b>YE 31 Dec (RMB mn)</b>						
<b>Current assets</b>	<b>17,289</b>	<b>18,544</b>	<b>19,970</b>	<b>20,128</b>	<b>23,075</b>	<b>26,416</b>
Cash & equivalents	7,377	10,059	9,629	9,753	12,484	15,613
Account receivables	314	289	477	438	487	534
Inventories	686	1,284	1,722	1,796	1,963	2,128
Prepayment	571	557	576	576	576	576
ST bank deposits	5,390	6,331	7,540	7,540	7,540	7,540
Other current assets	2,949	24	26	26	26	26
<b>Non-current assets</b>	<b>5,715</b>	<b>9,778</b>	<b>11,512</b>	<b>13,009</b>	<b>14,141</b>	<b>15,183</b>
PP&E	3,971	7,197	8,437	9,944	11,091	12,149
Right-of-use assets	377	366	428	428	428	428
Deferred income tax	209	376	474	474	474	474
Investment in JVs & assos	143	143	128	112	96	81
Intangibles	48	48	133	139	139	139
Other non-current assets	18,256	20,192	21,882	22,041	24,987	28,329
<b>Total assets</b>	<b>23,004</b>	<b>28,323</b>	<b>31,481</b>	<b>33,137</b>	<b>37,215</b>	<b>41,599</b>
<b>Current liabilities</b>	<b>7,439</b>	<b>7,107</b>	<b>6,942</b>	<b>6,898</b>	<b>7,022</b>	<b>7,145</b>
Short-term borrowings	3,094	448	313	213	213	213
Account payables	1,042	1,133	1,284	1,339	1,464	1,587
Tax payable	614	910	1,063	1,063	1,063	1,063
Other current liabilities	2,631	4,518	4,221	4,221	4,221	4,221
Lease liabilities	57	98	62	62	62	62
<b>Non-current liabilities</b>	<b>2,536</b>	<b>2,030</b>	<b>2,136</b>	<b>2,036</b>	<b>1,936</b>	<b>1,936</b>
Long-term borrowings	1,716	732	621	521	421	421
Obligations under finance leases	128	139	115	115	115	115
Other non-current liabilities	691	1,158	1,399	1,399	1,399	1,399
<b>Total liabilities</b>	<b>9,974</b>	<b>9,137</b>	<b>9,078</b>	<b>8,933</b>	<b>8,958</b>	<b>9,081</b>
Share capital	0	0	0	0	0	0
Retained earnings	13,030	17,747	20,921	22,688	26,709	30,936
Other reserves	0	0	0	0	0	0
<b>Total shareholders equity</b>	<b>13,030</b>	<b>17,747</b>	<b>20,921</b>	<b>22,688</b>	<b>26,709</b>	<b>30,936</b>
Minority interest	0	1,438	1,482	1,515	1,549	1,582
<b>Total equity and liabilities</b>	<b>23,004</b>	<b>28,323</b>	<b>31,481</b>	<b>33,137</b>	<b>37,215</b>	<b>41,599</b>

<b>CASH FLOW</b>	<b>2019A</b>	<b>2020A</b>	<b>2021A</b>	<b>2022E</b>	<b>2023E</b>	<b>2024E</b>
<b>YE 31 Dec (RMB mn)</b>						
<b>Operating</b>						
Profit before taxation	5,683	9,900	9,672	7,361	8,596	9,380
Depreciation & amortization	181	266	443	510	601	684
Tax paid	(1,748)	(2,464)	(2,757)	(2,098)	(2,451)	(2,674)
Change in working capital	562	1,253	(827)	21	(91)	(90)
Others	503	(1,204)	284	16	16	16
<b>Net cash from operations</b>	<b>5,181</b>	<b>7,751</b>	<b>6,815</b>	<b>5,809</b>	<b>6,671</b>	<b>7,316</b>
<b>Investing</b>						
Capital expenditure	(1,401)	(816)	(1,930)	(2,023)	(1,748)	(1,742)
Acquisition of subsidiaries/ investments	0	(757)	(286)	0	0	0
Net proceeds from disposal of short-term investments	0	0	16	16	16	16
Others	(4,114)	(2,213)	(244)	(16)	(16)	(16)
<b>Net cash from investing</b>	<b>(5,515)</b>	<b>(3,786)</b>	<b>(2,444)</b>	<b>(2,023)</b>	<b>(1,748)</b>	<b>(1,742)</b>
<b>Financing</b>						
Dividend paid	(2,704)	(2,685)	(3,392)	(3,462)	(2,092)	(2,445)
Net borrowings	3,070	(3,630)	(444)	(200)	(100)	0
Proceeds from share issues	5,984	0	(365)	0	0	0
Others	(2,226)	3,772	(44)	0	0	0
<b>Net cash from financing</b>	<b>4,123</b>	<b>(2,543)</b>	<b>(4,245)</b>	<b>(3,662)</b>	<b>(2,192)</b>	<b>(2,445)</b>
<b>Net change in cash</b>						
Cash at the beginning of the year	3,641	7,377	10,059	9,629	9,753	12,484
Exchange difference	(18)	(173)	(49)	0	0	0
Others	(34)	1,433	(506)	0	0	0
<b>Cash at the end of the year</b>	<b>7,377</b>	<b>10,059</b>	<b>9,629</b>	<b>9,753</b>	<b>12,484</b>	<b>15,613</b>
<b>GROWTH</b>	<b>2019A</b>	<b>2020A</b>	<b>2021A</b>	<b>2022E</b>	<b>2023E</b>	<b>2024E</b>
<b>YE 31 Dec</b>						
Revenue	na	35.5%	22.5%	(7.0%)	11.1%	9.8%
Gross profit	na	40.3%	18.7%	(11.8%)	12.1%	10.5%
Operating profit	na	73.7%	0.0%	(24.9%)	16.7%	9.1%
EBITDA	na	72.9%	1.8%	(23.2%)	16.7%	9.4%
Net profit	na	89.0%	(7.6%)	(23.9%)	16.9%	9.2%
<b>PROFITABILITY</b>	<b>2019A</b>	<b>2020A</b>	<b>2021A</b>	<b>2022E</b>	<b>2023E</b>	<b>2024E</b>
<b>YE 31 Dec</b>						
Gross profit margin	70.0%	72.5%	70.3%	66.7%	67.2%	67.6%
Operating margin	41.3%	52.9%	43.2%	34.9%	36.6%	36.4%
EBITDA margin	42.6%	54.4%	45.2%	37.3%	39.2%	39.0%
Return on equity (ROE)	na	48.3%	35.5%	24.0%	24.7%	23.1%
<b>GEARING/LIQUIDITY/ACTIVITIES</b>	<b>2019A</b>	<b>2020A</b>	<b>2021A</b>	<b>2022E</b>	<b>2023E</b>	<b>2024E</b>
<b>YE 31 Dec</b>						
Net debt to equity (x)	0.2	(0.1)	(0.0)	(0.0)	(0.1)	(0.2)
Current ratio (x)	2.3	2.6	2.9	2.9	3.3	3.7
Receivable turnover days	8.2	5.6	7.5	7.5	7.5	7.5
Inventory turnover days	60.9	91.7	92.8	92.8	92.8	92.8
Payable turnover days	92.5	80.9	69.2	69.2	69.2	69.2
<b>VALUATION</b>	<b>2019A</b>	<b>2020A</b>	<b>2021A</b>	<b>2022E</b>	<b>2023E</b>	<b>2024E</b>
<b>YE 31 Dec</b>						
P/E	14.1	15.9	18.6	9.3	8.0	7.3
P/E (diluted)	14.2	16.2	19.0	9.5	8.1	7.4
P/B	4.3	6.6	6.1	2.1	1.8	1.6
Div yield (%)	2.8	1.9	2.7	4.3	5.0	5.5

Source: Company data, CMBIGM estimates. Note: The calculation of net cash includes financial assets.

## Disclosures & Disclaimers

### Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an

officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

## CMBIGM Ratings

<b>BUY</b>	: Stock with potential return of over 15% over next 12 months
<b>HOLD</b>	: Stock with potential return of +15% to -10% over next 12 months
<b>SELL</b>	: Stock with potential loss of over 10% over next 12 months
<b>NOT RATED</b>	: Stock is not rated by CMBIGM
<b>OUTPERFORM</b>	: Industry expected to outperform the relevant broad market benchmark over next 12 months
<b>MARKET-PERFORM</b>	: Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
<b>UNDERPERFORM</b>	: Industry expected to underperform the relevant broad market benchmark over next 12 months

## CMB International Global Markets Limited

**Address:** 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

**CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)**

## Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM.

Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.") of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.